Clinical Trial Results - Progress in Cancer Care
These summaries highlight recently released results from cancer clinical trials. The findings are significant enough that they are likely to influence your medical care.
The summaries are listed in reverse chronological order. You may also use the navigation tools on the left to search the summaries by keyword or type of cancer.
1. Maintenance Rituximab May Improve Survival in Follicular Lymphoma
(Posted: 04/02/2009) - Follicular lymphoma patients who receive maintenance therapy with rituximab after their disease goes into remission may have better survival than those who do not receive such therapy, according to the February 18, 2009, issue of Journal of the National Cancer Institute.
2. Azacitidine Improves Survival in Myelodysplastic Syndromes
(Posted: 03/26/2009) - The DNA methyltransferase inhibitor azacitidine (Vidaza®) improved overall survival in patients with higher-risk myelodysplastic syndromes, according to the March 2009 issue of Lancet Oncology.
3. U.S. Cancer Screening Trial Shows No Early Mortality Benefit from Annual Prostate Cancer Screening
(Posted: 03/18/2009) - Six annual screenings for prostate cancer led to more diagnoses of the disease, but no fewer prostate cancer deaths, according to a major new report from the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial, a 17-year project of the NCI. The PLCO was designed to provide answers about the effectiveness of prostate cancer screening.
4. Radiation Therapy Helps Prevent DCIS Recurrence After Breast-Conserving Surgery
(Posted: 03/10/2009) - The addition of radiation therapy to breast-conserving surgery halves the risk of a tumor recurrence compared with surgery alone in women with noninvasive breast tumors, according to a pooled analysis of trial results published January 21, 2009, by the Cochrane Reviews.
5. Double Transplantation of One's Own Stem Cells Is Not Warranted for Multiple Myeloma
(Posted: 02/24/2009) - The addition of a second hematopoietic stem cell transplant procedure using one's own blood cells does not appear warranted in multiple myeloma, according to the Jan. 21, 2009, Journal of the National Cancer Institute.
1 2 3 4 Next >
|
